Literature DB >> 20508211

Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.

C Ashley Finlen Copeland1, Laurie D Snyder, David W Zaas, W Jackson Turbyfill, W Austin Davis, Scott M Palmer.   

Abstract

RATIONALE: Despite the importance of bronchiolitis obliterans syndrome (BOS) in lung transplantation, little is known regarding the factors that influence survival after the onset of this condition, particularly among bilateral transplant recipients.
OBJECTIVES: To identify factors that influence survival after the onset of BOS among bilateral lung transplant recipients.
METHODS: The effect of demographic or clinical factors, occurring before BOS, upon survival after the onset of BOS was studied in 95 bilateral lung transplant recipient using Cox proportional hazards models.
MEASUREMENTS AND MAIN RESULTS: Although many factors, including prior acute rejection or rejection treatments, were not associated with survival after BOS, BOS onset within 2 years of transplantation (early-onset BOS), or BOS onset grade of 2 or 3 (high-grade onset) were predictive of significantly worse survival (early onset P = 0.04; hazard ratio, 1.84; 95% confidence interval, 1.03-3.29; high-grade onset P = 0.003; hazard ratio, 2.40; 95% confidence interval, 1.34-4.32). The effects of both early onset and high-grade onset on survival persisted in multivariable analysis and after adjustment for concurrent treatments. Results suggested an interaction might exist between early onset and high-grade onset. In particular, high-grade onset of BOS, regardless of its timing after transplant, is associated with a very poor prognosis.
CONCLUSIONS: The course of BOS after bilateral lung transplantation is variable. Distinct patterns of survival after BOS are evident and related to timing or severity of onset. Further characterization of these subgroups should provide a more rational basis from which to design, stratify, and assess response in future BOS treatment trials.

Entities:  

Mesh:

Year:  2010        PMID: 20508211      PMCID: PMC2949403          DOI: 10.1164/rccm.201002-0211OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

Review 1.  Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.

Authors:  Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem
Journal:  J Heart Lung Transplant       Date:  2002-03       Impact factor: 10.247

2.  Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome.

Authors:  Christopher M Burton; Jørn Carlsen; Jann Mortensen; Claus B Andersen; Nils Milman; Martin Iversen
Journal:  J Heart Lung Transplant       Date:  2007-07       Impact factor: 10.247

3.  Lung transplantation at Duke University Medical Center.

Authors:  Laurie D Snyder; Ashley Finlen-Copeland; Matthew G Hartwig; Shu S Lin; R Duane Davis; Scott M Palmer
Journal:  Clin Transpl       Date:  2007

4.  Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.

Authors:  S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar
Journal:  J Heart Lung Transplant       Date:  1996-01       Impact factor: 10.247

5.  Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation.

Authors:  H Reichenspurner; R E Girgis; R C Robbins; K L Yun; M Nitschke; G J Berry; R E Morris; J Theodore; B A Reitz
Journal:  Ann Thorac Surg       Date:  1996-11       Impact factor: 4.330

6.  Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life.

Authors:  J W van Den BERG; A Geertsma; W van Der BIJ; G H Koëter; W J de BOER; D S Postma; E M ten VERGERT
Journal:  Am J Respir Crit Care Med       Date:  2000-06       Impact factor: 21.405

7.  Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.

Authors:  D Heng; L D Sharples; K McNeil; S Stewart; T Wreghitt; J Wallwork
Journal:  J Heart Lung Transplant       Date:  1998-12       Impact factor: 10.247

8.  Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?

Authors:  Christopher H Jackson; Linda D Sharples; Keith McNeil; Susan Stewart; John Wallwork
Journal:  J Heart Lung Transplant       Date:  2002-06       Impact factor: 10.247

9.  Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis.

Authors:  V G Valentine; R C Robbins; G J Berry; H R Patel; H Reichenspurner; B A Reitz; J Theodore
Journal:  J Heart Lung Transplant       Date:  1996-04       Impact factor: 10.247

10.  Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients.

Authors:  Vibha N Lama; Susan Murray; Robert J Lonigro; Galen B Toews; Andrew Chang; Christine Lau; Andrew Flint; Kevin M Chan; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-03-08       Impact factor: 21.405

View more
  40 in total

1.  Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.

Authors:  Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen
Journal:  J Heart Lung Transplant       Date:  2018-09-25       Impact factor: 10.247

2.  Fibroproliferation in chronic lung allograft dysfunction: Association of mesenchymal cells in bronchoalveolar lavage with phenotypes and survival.

Authors:  Michael P Combs; Meng Xia; David S Wheeler; Elizabeth A Belloli; Natalie M Walker; Russell R Braeuer; Dennis M Lyu; Susan Murray; Vibha N Lama
Journal:  J Heart Lung Transplant       Date:  2020-04-19       Impact factor: 10.247

3.  Distal airway microbiome is associated with immunoregulatory myeloid cell responses in lung transplant recipients.

Authors:  Nirmal S Sharma; Keith M Wille; S Athira; Degui Zhi; Kenneth P Hough; Enrique Diaz-Guzman; Kui Zhang; Ranjit Kumar; Sunad Rangarajan; Peter Eipers; Yong Wang; Ritesh K Srivastava; Jose Vicente Rodriguez Dager; Mohammad Athar; Casey Morrow; Charles W Hoopes; David D Chaplin; Victor J Thannickal; Jessy S Deshane
Journal:  J Heart Lung Transplant       Date:  2017-07-15       Impact factor: 10.247

4.  25-year follow-up after lung transplantation at Lund University Hospital in Sweden: superior results obtained for patients with cystic fibrosis.

Authors:  Mohammed Fakhro; Richard Ingemansson; Ingrid Skog; Lars Algotsson; Lennart Hansson; Bansi Koul; Ronny Gustafsson; Per Wierup; Sandra Lindstedt
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-04-06

5.  Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.

Authors:  Ariss DerHovanessian; Jamie L Todd; Alice Zhang; Ning Li; Aradhna Mayalall; C Ashley Finlen Copeland; Michael Shino; Elizabeth N Pavlisko; W Dean Wallace; Aric Gregson; David J Ross; Rajan Saggar; Joseph P Lynch; John Belperio; Laurie D Snyder; Scott M Palmer; S Sam Weigt
Journal:  Ann Am Thorac Soc       Date:  2016-05

Review 6.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 7.  The role of the immune system in lung transplantation: towards improved long-term results.

Authors:  Ramsey R Hachem
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

8.  Longitudinal Forced Vital Capacity Monitoring as a Prognostic Adjunct after Lung Transplantation.

Authors:  Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

9.  Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

10.  Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

Authors:  Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.